Ipratropiumbromide Newline Pharma (Ipratropium Bromide Monohydrate)

Ipratropium bromide works by competitively blocking muscarinic (M1 and M3) acetylcholine receptors on airway smooth muscle and submucosal glands. This inhibition prevents acetylcholine‑induced bronchoconstriction and mucus secretion, leading to bronchodilation and easier airflow.

The dose is individualized by the prescribing healthcare professional based on the patient’s condition, severity, and response. Ipratropium bromide is typically administered via nebulizer or metered‑dose inhaler, and the exact regimen should follow the prescriber’s instructions.

Pregnancy safety data are limited and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult their physician, as small amounts may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

The primary alternative is a short‑acting beta‑agonist such as albuterol. While beta‑agonists stimulate bronchodilation via β2‑receptor activation, ipratropium provides anticholinergic bronchodilation by blocking muscarinic receptors. Ipratropium is often used when beta‑agonists are insufficient or as add‑on therapy for synergistic effect.

Store the inhalation solution at room temperature below 25 °C, in the original packaging, protected from moisture and direct light. Do not freeze the product. Keep the container tightly closed when not in use to maintain stability.

The medication is delivered by inhalation, either through a nebulizer solution or a metered‑dose inhaler (MDI). Patients should follow device‑specific instructions, inhale slowly and deeply, and hold their breath for a few seconds to allow optimal drug deposition in the lungs.

Serious adverse events, although rare, include paradoxical bronchospasm (worsening of breathing difficulty), angioedema (swelling of face, lips, or tongue), and urinary retention, especially in patients with pre‑existing prostate enlargement or bladder outlet obstruction.

Patients with known hypersensitivity to ipratropium bromide or any formulation excipients should avoid the product. It is also contraindicated in individuals with narrow‑angle glaucoma, severe urinary retention, or those who have experienced a previous paradoxical bronchospasm while using anticholinergic inhalers.